Therapeutic Pipeline:
Available for Licensing
With extensive experience, Divamics has transformed its validated expertise into proprietary in-house pipelines. These assets are designed to address critical unmet medical needs and are supported by robust preclinical data and IND-enabling packages, offering strategic licensing opportunities.
Inflammatory Bowel Disease
DVI-001 is a cyclic peptide program for inflammatory bowel disease, developed using Divamics’ AI-enabled multi-scale simulation platform. The asset has undergone early optimization and demonstrates strong developability potential as it advances toward PCC. Partnership and licensing opportunities are available.
Inflammatory Bowel Disease
DVI-002 is a bispecific antibody program for inflammatory bowel disease, supported by AI-driven structural modeling and developability assessment. The project shows promising dual-target potential and is currently in early discovery and lead optimization. Open for collaboration and co-development.
Diabetes and Obesity
DVI-003 is a small-molecule program targeting diabetes and obesity, leveraging AI-driven design and early-stage optimization. The asset demonstrates favorable properties for further advancement and is available for licensing or co-development discussions.
Interested in partnership or licensing opportunities?
Let’s explore how our pipeline assets can accelerate your R&D strategy
